Biologic therapies for chronic inflammatory bowel disease;Tratamientos biológicos en la enfermedad inflamatoria crónica intestinal

Revista Espanola de Enfermedades Digestivas

Volumn 98, Issue 4, 2006, Pages 265-291

  Martinez Montiel M P ^a   Munoz Yague M T ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Crohn's disease; Inflammatory bowel disease; Therapy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA4 INTEGRIN; AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; ETANERCEPT; FONTOLIZUMAB; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; MLN 02; NATALIZUMAB; OKT 4; ONERCEPT; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; MONOCLONAL ANTIBODY;

ANOREXIA; BONE PAIN; BRAIN DISEASE; CD4 LYMPHOCYTE COUNT; CHROMOSOME 5; CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG WITHDRAWAL; ENTERITIS; GRANULOCYTE; HEART FAILURE; HUMAN; IMMUNOSTIMULATION; INFECTION; INJECTION SITE REACTION; LETHARGY; LEUKOCYTE COUNT; LUPOID SYNDROME; LUPUS ERYTHEMATOSUS; LYMPHOMA; MIGRAINE; MONOCYTE; NEUTROPHILIA; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WEAKNESS; BIOLOGICAL THERAPY; CELL ADHESION; DRUG ANTAGONISM; DRUG EFFECT; REVIEW;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CELL ADHESION; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846401140     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082006000400006     Document Type: Short Survey

References (113)

1. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 81-92.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn's Disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
3. Hanauer SB, Feagen BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
4. Sands BE, Anderson FH, Berstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl Med 2004; 350: 876-85.
5. Colombel JF, Loftus EV, Tremain JW, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
6. Sands BE. Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 1997; 3: 95-113.
7. Laroux FS, Pavlick KP, Wolf RE, et al. Dysregulation of intestinal mucosal immunity: implications in inflammatory bowel disease. News Physiol Sci 2001; 16: 272-7.
8. Melmed GY, Abreu MT. New insights into pathogenesis of inflammatory Bowel disease. Current Gastroenterology Reports 2004; 6: 474-81.
9. Shanahan F. Crohn's disease. Lancet 2002; 359: 62-9.
10. Lim WCh, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. Reviews in Gatroenterological Disorders 2004; 4: 66-84.
11. Sonnenburg JL, Angenent LT, Gordon JL. Getting a grip on things: How do communities of bacterial symbiots become established in our intestine? Nat Immunity 2004; 5: 569-73.
12. Goke M, Podolsky DK. Regulation of the mucosal epithelial barrier. Bailleres Clin Gatroenterol 1996; 10: 393-405.
13. Bouma G, Strober W. The immunological and genetics basis of inflammatory bowel disease. Nat Rev Immunol 2033; 3: 521-33.
14. Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84-8.
15. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-7.
16. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-6.
17. de Baey A, Mendel I, Baretton G, et al. A subset of human dendritic cell in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Inmunol 2003; 170: 5089-94.
18. Hugot JP, Chamaillard M, Zoulai H, et al. Association of NOD2 leukocyterich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
19. Ogura Y, Boren DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
20. Maeda S, Hsu LCh, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-[kappa] B activity and IL-1 [beta] processing Science 2005; 307: 734-8.
21. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003; 52: 1591-7.
22. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-medaited T helper type 1 response. Nat Immunol 2004; 5: 800-8.
23. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet 2004; 36: 471-5.
24. Ho G-T, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005; 128: 288-96.
25. Torok HP, Glas J, Tonenchi L, et al. Crohn's disease is associated with toll-like receptor-9 polymorphism. Gastroenterology 2004; 127: 365-6.
26. Torok HP, Glas J, Tonenchi L, et al. Polymorphisms of the lipopolysacaride-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 2004; 112: 85-91.
27. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-73.
28. Rugeerts P, Van Assche G, Vermiere S, et al. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126 (6): 1593-6.
29. Mendoza JL, Taxonera C, Lana R, et al. Diagnostic and treatment recommendations on perianal Crohn's disease. Rev Esp Enferm Dig 2005; 97: 46-56.
30. Vermiere S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: A prospective cohort study. Gastroenterology 2003; 125: 32-9.
31. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
32. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
33. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
34. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-5.
35. Hanauer SB, Wagner CL, Mayer L, et al. Incidence and importance of antibody response to infliximab in Crohn's disease. Clin Gastrol Hepatol 2004; 2(7): 542-53.
36. Baido L, Lichtenstein G. What next after Infliximab? Am J Gastroenterol 2005; 100: 80-3.
37. Mendoza JL, García Paredes J, Cruz Santamaría DM, et al. Infliximab treatment and prognostic factors for response in patients with Crohn's disease. Rev Esp Enferm Dig 2002; 94: 269-79.
38. Feagan BG, Sandborn WJ, Baker J, et al. A randomized, doubleblind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP57) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000; 118: A655.
39. Celltech announces results from CDP 571 Phase III studies in Crohn's disease. Celltech: Internet Press Release, 2002 (htt: //celltechgroup.com).
40. Schreiber S, Rutgeerts P, Fedorak R, et al. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology 2003; 124: A61.
41. Fegean B, Rutgeerts S, Schreiber S, et al. Low baseline CRP correlates with a high placebo remission rate in Crohn's disease (CD) clinical trial at 12 weeks. Gastroenterology 2005; 128 (Supl. 2): A-307.
42. Winter T, Wright J, Ghosh S, et al. Intravenous CDP870, a humanized anti-TNF antibody fragment, in patients with active Crohn's disease - an exploratory study. Gastroenterology 2003; 124: A377.
43. Sambord WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
44. Rutgeets P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open-labed, pilot study. Aliment Pharmacol Ther 2003; 17: 185-92.
45. Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2044; 126: A 53-4.
46. Hannauer SB, Lukas M, MacIntosh D, et al. A randomized, double-bind, placebo-controlled trial of the human antiTNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 2004; 127: 332-8.
47. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and Efficacy of adalimumab (D2E7) in Crohn's disease patient with attenuated response to Infliximab. Am. J Gastroenterol 2005; 100: 75-9.
48. Paulson SK, Noertersheuser P, Pollack PF, et al. Pharmacokinetics of Adalimumab from classic, a randomized phase III trial for the induction of clinical remission in patients with Crohn's. Gastroenterol 2005; 128 (Supl. 2): W 105.
49. Ito H, Takazoe M, Fukuda Y, et al. Effective treatment of active Crohn's disease with humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized placebo-controlled trial (abstract). Gastroenterology 2003; 124: A25.
50. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-74.
51. Rennick DM, Fort MM. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am. J Phiysiol Gastrointest Liver Physiol 2000; 278: G829-G833.
52. van Denver SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.Gastroenteology 1997; 113: 383-9.
53. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119: 1461-72.
54. Fedorak R, Nielsen O, Williams N, et al. Human recombinant interleukin-10 is safe and well tolerated but does nor induce remission in steroid dependent Crohn's disease (abstract). Gastroenterology 2001; 120: A127.
55. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1355-5.
56. Sasaki M, Joh T, Kataoka H, et al. IL-10 gene therapy for experimental colitis. Gastroenterol 2005; 128 (Supl. 2): S1378: A-204.
57. Nakase H, Okazaki K, Tabata Y, et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther 2002; 301: 59-65.
58. Braat H, Rottiers P, Huyghebaert N, et al. Interleukin-10 producing [i]lactocuccus Lactis [/i] for treatment of Crohn's disease. Gastroenterol 2005; 128 (Supl. 2): No 685: A-104.
59. Sands BE, Bank S, Sninsky CA. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patient with active Crohn's disease. Gastroenterology 1999; 117: 58-64.
60. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16: 399-406.
61. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
62. Samdborn W, Colombel J, Enns R, et al. Efficacy of natalizumab in maintaining clinical response and remission in Crohn's disease: comparison of sustained response and remission rates through 12 months vs. point-in-time response and remission rates at month 12 [abstract]. Gastroenterol 2005; 128 (Supl. 2): A-586.
63. Panaccione R, Colombel J, Enns B, et al. Efficacy of natalizumab in patients with Crohn's disease and prior history of infliximab therapy: 12 month results from Enact-2 [abstract]. Gastroenterol 2005; 128 (Supl. 2): A584.
64. Targan S, Colombel J, Enns R, et al. Maintenance therapy with natalizumab (enact-2) for patients with active Crohn's disease despite immunosuppressant use [abstract]. Gastroenterol 2005; 128 (Supl. 2): A-587.
65. Van Assche G, Van Ranst M, Sciot R, et al. Brief report: progressive multifocal leukoencefalophalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353 (4): 362-8.
66. Feagan BG, Greemberg G, Wild G, et al. Efficacy and safety of a humanized alpha4 beta4 antibody in active Crohn's disease [abstract]. Gastroenterology 2003; 124: A25.
67. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42.
68. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002; 51: 30-6.
69. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-Interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-79.
70. Rugeerts P, Reinisch W, Colombel JF, et al. Preliminary results of a phase I/II study of Huzaf, an anti-INF-gamma monoclonal antibody, in patient with moderate to severe active Crohn's disease. Gastroenterology 2002; 122: A-61.
71. Protein design Labs reports progress on two humanized antibodies at International Organization of Inflammatory Bowel Disease. Internet Press Release, 2004 (http: /www.pdl.com).
72. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal INF-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1264-R1273.
73. Sandborn WJ and Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-608.
74. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342: 1633-7.
75. Solis Herruzo JA, Fernández Baya B, Villalta Castel E, et al. Diminished cytochrome G599 content and toxic oxygen metabolite production circulating neutrophils from patients with Crohn's disease. Dig Dis Sci 1993; 38: 1631-7.
76. Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GMGSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun 2003; 312: 897-902.
77. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360: 1478-80.
78. Korzenik J, Dieckgraefe B. Immunostimulation in Crohn's disease: results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn's disease. Gastroenterology 2000; 118: A874.
79. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostin for active Crohn's disease. N Engl J Med 2005; 352: 2193-201.
80. Hanauer S, Baert F, Robinson M. Interferon treatment in mild to moderate active Crohn's disease: preliminary results of an open label pilot study [abstract]. Gastroenterology 1994; 106: A696.
81. Gasche C, Reinich W, Vogelsang H, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995; 40: 800-4.
82. Vantrapen G, Coremans G, Billiau A, et al. Treatment of Crohn's disease with interferon. A preliminary clinical trial. Acta Clin Belg 1980; 35: 238-42.
83. Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroidrefractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001; 113: 930-3.
84. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18: 175-81.
85. Kohn A, Prantera C, Pera A, et al. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci 2004; 8: 235-7.
86. Eldelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflammatory Bowel Dis 2005; 11: 213-8.
87. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1167-71.
88. Probert CS, Hearing SD, Schereiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut 2003; 7: 998-1002.
89. Rutgeerts P, Feagen BG, Olson A, et al. A randomized placebo-controlled trial of Infliximab therapy for active ulcerative colitis: ACT 1 trial [abstract]. Gastroenterology 2005; 128: A 689.
90. Sandborn WJ, Rachmilewitz D, Hanauer SB, et al. Infliximab induction and maintenance therapy for ulcerative colitis: ACT 2 trial. Gastroenterology 2005; 128: A688.
91. Travis SPL, Yap LM, Hawkey CJ, et al. RDP-58: novel and effective therapy for ulcerative colitis: results of parallel, prospective, placebocontrolled trials [abstract]. Am J Gastroenterol 2003; 98: S239.
92. Lofberg R, Neurath M, Ost A, et al. Topical NF?B p65 antisense oligonucleotides in patients with active distal colonic IBD. A randomized, controlled pilot trial [abstract]. Gastroenterology 2002; 122: A60.
93. Feagen B, McDonald JWD, Greenberg G, et al. An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis. Gastroenterology 2000; 118: (Supl.): A874.
94. Feagen B, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 2005; 352: 2499-507.
95. Phase II study of antisense drug ISIS 2302 demonstrates significant and long-lasting improvement of symptoms in patients with ulcerative colitis. Internet Press Release, 2001 (http: /www.isip.com).
96. Miner P, Wedel M, Bane B, et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19: 281-6.
97. van Deventer SJ, Volfova M, Flisiak R, et al. A phase 2 dose ranging, double-blind, placebo-controlled study of Alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis [abstract]. Gastroenterology 2005; 128: A74.
98. Miner PB, Geary RS, Matson J, et al. An open-label study to assess the pk and pharmacologic activity of Alicaforsen in patient with active ulcerative colitis [abstract]. Gastroenterology 2005; 128: A583.
99. Walker KB, Potter JM, House AK. Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance. Clin Exp Immunol 1987; 68: 162-7.
100. Kam JC, Szefler SJ, Surs W, et al. Combination IL-2 and IL-4 reduces glucocorticoids. J Immunol 1993; 151: 3460-6.
101. Van Asschen G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti- interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98: 369-76.
102. Claessens C, Van As sche G, Dalle I, et al. Clinical improvement precedes mucosal healing in ulcerative colitis treated with anti- IL-2 agents [abstract]. Gastroenterology 2002; 122: A31.
103. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids, may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 65-75.
104. Plevy SE, Salzberg BA, Regueiro M, et al. A humanized anti-CD3 antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: preliminary results of a phase I study [abstract]. Gastroenterology 2003; 124: A7.
105. Keller S, Delanoy M, Zhao V, et al. Treatment with visilizumab causes a rapid and reversible increase in circulating levels of selected cytokines and growth factors in patients with intravenous steroid-refractory ulcerative colitis [abstract]. Gastroenterology 2005; 128: A579.
106. Hommes D, Plevy S, Salzberg BA, et al. Epstein-Barr virus (EBV) replication in sever active, steroid resistant ulcerative colitis (CU) patients treated with visilizumab, an anti-Cde antibody [abstract]. Gastroenterology 2005; 128: A75.
107. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin [keratinocyte growth factor-2] for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003; 17: 1355-64.
108. Mahmood A, Melley L, Fitzgerald A, et al. Phase I/II trial of trefoil factor family 3 (tff-3) enema therapy with oral mesalazine for mild to moderate left sided colitis [abstract]. Gastroenterology 2005; 128: A581.
109. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-7.
110. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 597-602.
111. Tilg H, Vogelsang H, Ludwiczek O, et al. A randomized placebo-controlled trial of pegylated interferon alpha in active colitis [abstract]. Gastroenterology 2003; 124: A62.
112. Musch E, Raedler A, Andus T, et al. A phase II placebo-controlled, randomized, multicenter study to evaluate efficiency and safety of interferon beta-1a in patients with ulcerative colitis [abstract]. Gastroenterology 2002; 122: A431.
113. Nikolaus S, Rugeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomized, dose escalating study. Gut 2003; 52: 1286-90.